Today, we want to delve into the exciting world of Rovalpituzumab tesirine. Whether we are talking about the history of Rovalpituzumab tesirine, its impact on society today, or its possible applications in the future, Rovalpituzumab tesirine is a topic that never ceases to amaze us. Throughout this article, we will explore the different aspects of Rovalpituzumab tesirine, from its origins to its implications in daily life. Regardless of whether you are an expert on the subject or are just discovering its existence, we invite you to immerse yourself in this fascinating universe and discover everything that Rovalpituzumab tesirine has to offer us.
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized |
Target | DLL3 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6416H9894N1698O2028S46 (non-glycosylated) |
Rovalpituzumab tesirine (Rova-T) is an experimental antibody-drug conjugate targeting the protein DLL3 on tumor cells. It was originally developed by Stemcentrx and was purchased by AbbVie. It was tested for use in small-cell lung cancer, but development was terminated after unsuccessful phase III trial.
In 2018, an Independent Data Monitoring Committee found that in the TAHOE phase III trial, Rova-T shortened survival of lung cancer patients compared to SOC chemotherapy topotecan, prompting termination of trial enrollment. Another phase III trial (MERU) demonstrated no survival benefit over placebo. A phase II trial using the drug as a third-line treatment for relapsed or refractory lung cancer showed objective response rate at just 16%.
Chemical structure of "tesirine" (drawn in black). It consists of a pyrrolobenzodiazepine type dimer (top), which is the actual anti-cancer agent, a Val–Ala structure that can be cleaved by an enzyme to detach the anti-cancer agent from the antibody, a polyethylene glycol spacer, and a maleimide linker which is attached to a cysteine in the antibody's (rovalpituzumab's) peptide backbone, drawn blue. Each rovalpituzumab molecule has an average of two such attachments.
{{cite web}}
: CS1 maint: multiple names: authors list (link) CS1 maint: numeric names: authors list (link)